2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia
暂无分享,去创建一个
Charles King | Blake Roessler | Nicola Dalbeth | Robert Terkeltaub | Neil Wenger | R. Terkeltaub | J. Singh | Hyon K. Choi | D. Furst | Gerald. D. Levy | F. Perez-Ruiz | W. Taylor | N. Wenger | V. Niyyar | D. Khanna | N. Dalbeth | B. Roessler | M. Pillinger | T. Neogi | Charles King | Mark L. Robbins | Susan Lee | Dinesh Khanna | Sangmee Bae | G. Kerr | J. Fitzgerald | P. Khanna | S. Bae | Manjit K. Singh | J. Merill | Susan Lee | Shraddha Prakash | Marian Kaldas | Maneesh Gogia | F. Lioté | Sanford Kaplan | Danielle Jones | S. Yarows | N. Edwards | B. Mandell | H. Schumacher | Hyon Choi | Tuhina Neogi | Marian Kaldas | Daniel E. Furst | Frédéric Lioté | John D. Fitzgerald | Puja P. Khanna | Manjit K. Singh | Michael H. Pillinger | Joan Merill | Shraddha Prakash | Maneesh Gogia | Fernando Perez‐Ruiz | Will Taylor | Jasvinder A. Singh | Sanford Kaplan | Vandana Niyyar | Danielle Jones | Steven A. Yarows | Gail Kerr | Gerald Levy | N. Lawrence Edwards | Brian Mandell | H. Ralph Schumacher | Mark Robbins | F. Pérez-Ruiz
[1] M. Dougados,et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) , 2004, Annals of the rheumatic diseases.
[2] N. Chaiyakunapruk,et al. Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis , 2011, BMC Medical Genetics.
[3] C. Fernández,et al. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. , 1999, The Journal of rheumatology.
[4] N. McGill. 6. Gout and other crystal arthropathies , 1997, The Medical journal of Australia.
[5] Jeffrey R Curtis,et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis , 2012, Arthritis care & research.
[6] J. Nolla,et al. Correction of Allopurinol Dosing Should Be Based on Clearance of Creatinine, but Not Plasma Creatinine Levels: Another Insight to Allopurinol-Related Toxicity , 2005, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[7] C. Weel,et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial , 2008, The Lancet.
[8] A. So,et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. , 2010, Arthritis and rheumatism.
[9] K. Chien,et al. Relationship between dietary patterns and serum uric acid concentrations among ethnic Chinese adults in Taiwan. , 2012, Asia Pacific journal of clinical nutrition.
[10] A. So,et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study , 2011, Arthritis Research & Therapy.
[11] R. Terkeltaub. Clinical practice. Gout. , 2003, The New England journal of medicine.
[12] K. Hande. Evaluation of a Thiazide‐Allopurinol Drug Interaction , 1986, The American journal of the medical sciences.
[13] H. Schumacher,et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. , 2008, Arthritis and rheumatism.
[14] H. Bueno,et al. NSAID Use Selectively Increases the Risk of Non-Fatal Myocardial Infarction: A Systematic Review of Randomised Trials and Observational Studies , 2011, PloS one.
[15] J. Levin,et al. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. , 1988, The Journal of rheumatology.
[16] R. Terkeltaub,et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. , 2010, Arthritis and rheumatism.
[17] G. Rebecca,et al. American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 2011 .
[18] H. Schumacher,et al. A survey of current evaluation and treatment of gout. , 2006, The Journal of rheumatology.
[19] S. Amur,et al. Allopurinol pharmacogenetics: assessment of potential clinical usefulness. , 2011, Pharmacogenomics.
[20] Hyon K. Choi,et al. Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort. , 2010, Arthritis and rheumatism.
[21] G L C ELLISTON,et al. Public Health Service , 1952 .
[22] S. Ottaviani,et al. [New therapeutic options for gout]. , 2011, Presse medicale.
[23] M. A. van de Laar,et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol , 2008, Annals of the rheumatic diseases.
[24] J. Heintzman,et al. NSAID prescribing precautions. , 2009, American family physician.
[25] A. Forsythe,et al. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy , 2011, Journal of medical economics.
[26] T. Rainer,et al. Oral prednisolone is more cost-effective than oral indomethacin for treating patients with acute gout-like arthritis , 2009, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.
[27] G. Karachalios,et al. Sulindac in the treatment of acute gout arthritis. , 1982, International journal of tissue reactions.
[28] M. Janssen,et al. Systemic corticosteroids for acute gout (Review) , 2008 .
[29] Hyon K. Choi. A prescription for lifestyle change in patients with hyperuricemia and gout , 2010, Current opinion in rheumatology.
[30] R. Willburger,et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. , 2007, Rheumatology.
[31] D. Nashel,et al. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. , 1993, The Journal of rheumatology.
[32] R. Wortmann,et al. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. , 2010, Clinical therapeutics.
[33] P. Lipsky,et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. , 2011, JAMA.
[34] P. Macdonald,et al. Determinants of the Clinical Outcomes of Gout During the First Year of Urate-Lowering Therapy , 2008, Nucleosides, nucleotides & nucleic acids.
[35] K. Hande,et al. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. , 1984, The American journal of medicine.
[36] C. Mancuso,et al. Anakinra's efficacy is variable in refractory gout: report of ten cases. , 2010, Seminars in arthritis and rheumatism.
[37] B. Joffe,et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study , 2000, Annals of the rheumatic diseases.
[38] A. Forsythe,et al. Chronic gout: epidemiology, disease progression, treatment and disease burden , 2010, Current medical research and opinion.
[39] M. A. van de Laar,et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout , 2008, Annals of the rheumatic diseases.
[40] M. Stevenson,et al. Febuxostat for the Management of Hyperuricaemia in Patients with Gout , 2011, PharmacoEconomics.
[41] 庄司 晃. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis : evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy , 2005 .
[42] R. Terkeltaub,et al. Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. , 2012, Arthritis and rheumatism.
[43] H. Schumacher,et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial , 2010, Arthritis research & therapy.
[44] D. Goldfarb,et al. Gout and its comorbidities. , 2010, Bulletin of the NYU hospital for joint diseases.
[45] A. So,et al. Extended Report , 2022 .
[46] M. Gutierrez,et al. Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: an ultrasound controlled study , 2011, Arthritis research & therapy.
[47] Hyon K. Choi,et al. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. , 2011, Arthritis and rheumatism.
[48] F. Perez-Ruiz,et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. , 2002, Arthritis and rheumatism.
[49] J. Singh,et al. Progress in Measurement Instruments for Acute and Chronic Gout Studies , 2009, The Journal of Rheumatology.
[50] R. Terkeltaub. Update on gout: new therapeutic strategies and options , 2010, Nature Reviews Rheumatology.
[51] M. Doherty,et al. Gout. Epidemiology of gout , 2010, Arthritis Research & Therapy.
[52] P Netter,et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.
[53] D. Goldfarb,et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. , 2011, The American journal of medicine.
[54] N. Kleinman,et al. The impact of gout on work absence and productivity. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[55] A. Romanowicz,et al. Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. , 1991, Current medical research and opinion.
[56] S. Nicolaou,et al. Dual energy computed tomography in tophaceous gout , 2008, Annals of the rheumatic diseases.
[57] J. Jung,et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[58] J. Hodges,et al. Quality of care for gout in the US needs improvement. , 2007, Arthritis and rheumatism.
[59] Hyon K. Choi,et al. Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide , 2011, Annals of the rheumatic diseases.
[60] H. Schumacher,et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. , 2005, The New England journal of medicine.
[61] K. Chan,et al. Comparison of Drug Adherence Rates Among Patients with Seven Different Medical Conditions , 2008, Pharmacotherapy.
[62] F. Perez-Ruiz,et al. Efficacy and Tolerability of Celecoxib in the Treatment of Acute Gouty Arthritis: A Randomized Controlled Trial , 2012, The Journal of Rheumatology.
[63] C. Cleeland,et al. Lessons learned from a multiple-dose post-operative analgesic trial , 2004, Pain.
[64] L. Kuller,et al. Long-term cardiovascular mortality among middle-aged men with gout. , 2008, Archives of internal medicine.
[65] H. Schumacher,et al. Local ice therapy during bouts of acute gouty arthritis. , 2002, The Journal of rheumatology.
[66] J. Ornato,et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .
[67] Gerald D. Groff,et al. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. , 1990, Seminars in arthritis and rheumatism.
[68] K. Williams,et al. Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status? , 2012, Internal medicine journal.
[69] P. Lucassen,et al. Systemic corticosteroids for acute gout. , 2008, The Cochrane database of systematic reviews.
[70] S. Tiamkao,et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population , 2009, Pharmacogenetics and genomics.
[71] J. Allison,et al. Measuring quality in arthritis care: the Arthritis Foundation's quality indicator set for analgesics. , 2004, Arthritis and rheumatism.
[72] M. Hochberg,et al. Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1996 .
[73] W. Willett,et al. Alcohol intake and risk of incident gout in men: a prospective study , 2004, The Lancet.
[74] G. Gamble,et al. Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography , 2008, Annals of the rheumatic diseases.
[75] N. Dalbeth,et al. Assessment of Tophus Size: A Comparison Between Physical Measurement Methods and Dual-Energy Computed Tomography Scanning , 2012, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[76] M. González-Gay,et al. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with Gout , 2010, Arthritis care & research.
[77] A. Taniguchi,et al. Comorbidities in Patients with Gout , 2011, Nucleosides, nucleotides & nucleic acids.
[78] W. Bilker,et al. Quality of care indicators for gout management. , 2004, Arthritis and rheumatism.
[79] P. Brooks,et al. Does colchicine work? The results of the first controlled study in acute gout. , 1987, Australian and New Zealand journal of medicine.
[80] H. Schumacher,et al. Dosing of antirheumatic drugs in renal disease and dialysis. , 2004, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[81] P Netter,et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.
[82] W. Willett,et al. Fructose-rich beverages and risk of gout in women. , 2010, JAMA.
[83] C. Vojir,et al. Determining mild, moderate, and severe pain equivalency across pain-intensity tools in nursing home residents. , 2007, Journal of rehabilitation research and development.
[84] J. Singh,et al. Risk factors for gout and prevention: a systematic review of the literature , 2011, Current opinion in rheumatology.
[85] N. Kleinman,et al. The economic burden of gout on an employed population , 2006, Current medical research and opinion.
[86] J. Tschopp,et al. A pilot study of IL-1 inhibition by anakinra in acute gout , 2007, Arthritis research & therapy.
[87] Roddy Edward,et al. Gout , 2011 .
[88] R. Terkeltaub,et al. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout , 2009, Current rheumatology reports.
[89] Y. Moriwaki,et al. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism , 2003, Annals of the rheumatic diseases.
[90] G. Lupton,et al. The allopurinol hypersensitivity syndrome. , 1979, Journal of the American Academy of Dermatology.
[91] I. F. Duff,et al. Long term uricosuric therapy in gout. , 1962, Arthritis and rheumatism.
[92] R. Terkeltaub,et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. , 2011, Arthritis and rheumatism.
[93] M. Ernst,et al. Management of gout in the older adult. , 2011, The American journal of geriatric pharmacotherapy.
[94] D. Khanna,et al. Health-Related Quality of Life and Outcome Measures in Gout , 2012 .
[95] Hyon K. Choi,et al. Purine-rich foods intake and recurrent gout attacks , 2012, Annals of the rheumatic diseases.
[96] S. Navarra,et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. , 2004, Arthritis and rheumatism.
[97] Hyon K. Choi,et al. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study , 2008, BMJ : British Medical Journal.
[98] J. Scott,et al. Multi-centre trial of naproxen and phenylbutazone in acute gout. , 1977, Advances in experimental medicine and biology.
[99] L. Naldi,et al. A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs , 2008, Pharmacogenetics and genomics.
[100] J. Burgers,et al. [Summary of the Dutch College of General Practitioners' (NHG) practice guideline 'The menopausal transition']. , 2012, Nederlands tijdschrift voor geneeskunde.
[101] Jeffrey R Curtis,et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. , 2008, Arthritis and rheumatism.
[102] M. Abel,et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. , 2004, The Journal of rheumatology.
[103] J. Brouwers,et al. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients , 2007, Clinical Rheumatology.
[104] J. Singh,et al. Developing a provisional definition of flare in patients with established gout. , 2012, Arthritis and rheumatism.
[105] Robert G. Godfrey,et al. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. , 1974, Arthritis and rheumatism.
[106] D. Hunter,et al. Alcohol consumption as a trigger of recurrent gout attacks. , 2006, The American journal of medicine.
[107] D. Khanna. American College of Rheumatology guidelines for management of gout , 2013 .
[108] J. Boice,et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis , 2002, BMJ : British Medical Journal.
[109] Elizabeth W Karlson,et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. , 2004, The New England journal of medicine.
[110] A. Hingorani,et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. , 2007, Rheumatology.
[111] M. Doherty,et al. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study , 2012, Annals of the rheumatic diseases.
[112] R. Terkeltaub,et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis , 2012, Arthritis care & research.
[113] M. Barclay,et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. , 2011, Arthritis and rheumatism.
[114] R. Terkeltaub,et al. Erratum: Novel evidence‐based colchicine dose‐reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P‐glycoprotein inhibitors; Association of PPP2CA Polymorphisms With Systemic Lupus Erythematosus Susceptibility in Multiple Ethnic Groups , 2011 .
[115] H. Schumacher,et al. Quality of Life and Disability in Patients with Treatment-Failure Gout , 2009, The Journal of Rheumatology.
[116] Lily P. H. Yang. Oral Colchicine (Colcrys®) , 2010, Drugs.
[117] D. Furst,et al. Gout and the risk of acute myocardial infarction. , 2006, Arthritis and rheumatism.
[118] R. Thiele,et al. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved , 2010, Rheumatology International.
[119] S. Ottaviani,et al. An exploratory ultrasound study of early gout. , 2011, Clinical and experimental rheumatology.
[120] Yuan-Tsong Chen,et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[121] R. Terkeltaub,et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. , 2012, Arthritis and rheumatism.
[122] J. Coresh,et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. , 2012, Arthritis and rheumatism.
[123] S. Andrade,et al. Adherence with urate-lowering therapies for the treatment of gout , 2009, Arthritis research & therapy.
[124] J. Peterson,et al. Clinical utility of dual-energy CT for evaluation of tophaceous gout. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.
[125] J. Sacristán,et al. Allopurinol Hypersensitivity Syndrome: A Review , 1993, The Annals of pharmacotherapy.
[126] P. Cameron,et al. Comparison of Oral Prednisolone/Paracetamol and Oral Indomethacin/Paracetamol Combination Therapy in the Treatment of Acute Goutlike Arthritis: A Double-Blind, Randomized, Controlled Trial , 2007, Annals of Emergency Medicine.
[127] K. Gorter,et al. [Summary of the Dutch College of General Practitioners' "Gout" Standard]. , 2002, Nederlands tijdschrift voor geneeskunde.
[128] I. Reid,et al. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial , 2012, Annals of the rheumatic diseases.
[129] W. Taylor,et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. , 2012, Arthritis and rheumatism.